Clinical Trials Directory

Trials / Completed

CompletedNCT01417026

Intranasal Oxytocin and Learning in Autism

Promoting Social Perceptual Learning With Oxytocin in Autism

Status
Completed
Phase
Phase 2
Study type
Interventional
Enrollment
36 (actual)
Sponsor
Robert Schultz · Academic / Other
Sex
Male
Age
12 Years – 17 Years
Healthy volunteers
Not accepted

Summary

The main objective of this study is to determine the safety and therapeutic potential of intranasal oxytocin in children and adolescents with autism spectrum disorder (ASD) when paired with a computer game intervention that is designed to enhance face perception skills.

Detailed description

Recognizing faces is critical to social functioning, and can be improved for individuals with ASD by using intervention software in the form of appropriately designed computer games. The effects of this type of social intervention may be amplified with the concurrent use of oxytocin. Furthermore, these learning effects may impact social skills in general and translate to the level of the individual's everyday social behavior. Thus, the objective of this study is to determine the safety and therapeutic potential of intranasal oxytocin in children and adolescents with ASD when paired with a computer game intervention that is designed to enhance face perception skills.

Conditions

Interventions

TypeNameDescription
DRUGIntranasal Oxytocin (Trade name: Syntocinon)This is a double-blind placebo-controlled trial of intranasal oxytocin in children and adolescents with ASD. Subjects will be randomized to 24 IU intranasal oxytocin or placebo for a 5 day period with concomitant game play of computer games, which are designed to enhance face perception skills. Measures of social function and cognition will be administered before and after the intervention period.

Timeline

Start date
2011-09-01
Primary completion
2015-04-01
Completion
2015-04-01
First posted
2011-08-16
Last updated
2017-03-30
Results posted
2017-03-30

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT01417026. Inclusion in this directory is not an endorsement.